GSK Jideytro (zidesamtinib)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Mature

Primary summary from verified readiness

Evidence strength Critical

Decision

Human editorial judgment · 2026-07-23

Track; not yet

Why: This is a real, FDA-approved (not speculative) drug with strong tier-2/3 sourcing and concrete efficacy numbers, but it is a single-indication (second-line-or-later) small-molecule approval in an already-served market (Xalkori/Rozlytrek/Augtyro) rather than a platform or broadly enabling technology — commercial and scientific differentiation (resistance-mutation coverage, tolerability) still needs to play out post-launch before it merits an "adopt" style posture on the register.
Next: Monitor confirmatory/post-marketing data (durability beyond 12 months, co-mutation resistance patterns, real-world safety) and GSK's parallel neladalkib (ALK) FDA decision expected 2026-11-27 from the same Nuvalent acquisition, since the two approvals together determine whether GSK's $10.6B lung-cancer bet becomes a genuine oncology-portfolio pivot vs. a single-asset win.

Constraints

No named blocker is present in the current public projection.

Evidence summary

AI-assisted assembly

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Initial public reading